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1. Introduction
The aims of this chapter are to briefly discuss infective conjunctivitis, its subtypes and its
treatment. Other forms of conjunctivitis will also be considered and discussed in this chap‐
ter, namely, neonatal conjunctivitis, conjunctivitis in the immunocompromised. A compre‐
hensive assessment of the various treatments of conjunctivitis will also be discussed.
Conjunctivitis is a term broadly used to describe an inflammation of the conjunctiva. Con‐
junctivitis may be split into four main aspects; bacterial, viral, allergic and irritant. Infective
conjunctivitis, namely bacterial and viral will be discussed in this chapter in details.
Figure 1. The conjunctiva in relation to the orbit and its structures
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1.1. Anatomy of the conjunctiva
The conjunctiva is the fine mucous membrane which covers and joins the anterior surface of
the eyeball to the posterior surface of eyelid. This translucent membrane lines the white part of
the eye starting at the edge of the cornea (limbus) and runs behind the eye to cover the anterior
part of the sclera. It then flows, loops forward, and forms the inside surface of the eyelids. At
the medial canthus the conjunctiva fold thickens, which is called the semilunar fold.
Figure 2. The different parts of the conjunctiva and its relation to other obit anatomy
The conjunctiva is subdivided into three parts depending on location: palpebral conjunctiva,
bulbar conjunctiva and conjunctival fornix. Histologically the conjunctiva is divided into
three layers.From superficial to deep these are epithelial, adenoid and fibrous. These con‐
junctival layers contain a wide range of structures that includes glands, melanocytes, langer‐
hans cells, mast cells and lymphoid tissue.
The arterial blood supply to conjunctiva is made up of branches of ophthalmic artery, the
anterior and posterior conjunctival arteries. These are branches of anterior ciliary arteries
and palpebral arcades respectively. The venous drainage follows the arteries. Posterior con‐
junctival veins drain the veins of the lid and anterior conjunctival veins drain anterior ciliary
vein to ophthalmic vein.
The lymphatic drainage of the conjunctiva depends on the region of the conjunctiva. Lym‐
phatics in palpebral region drain into the lymphatics of eyelids. In bulbar conjunctiva, lym‐
phatics from lateral side drain into the superficial preauricular lymph nodes & lymphatics
from medial side drain to deep sub maxillary nodes.
The first division of the trigeminal provides nerve supply to the conjunctiva.
1.2. Allergic and irritant conjunctivitis
Before discussing the major contents of the chapter, it is necessary to briefly discuss allergic
and irritant conjunctivitis.
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Figure 3. Allergic conjunctivitis- look for follicles and papillae which are characteristic of allergic conjunctivitis
Allergic conjunctivitis is seen in two acute disorders; seasonal allergic conjunctivitis (which
is prevalent in the summer months) and perennial allergic conjunctivitis (which presents in‐
termittently) and three chronic disorders, vernal keratoconjunctivitis, atopic keratoconjunc‐
tivitis and giant papillary conjunctivitis. Allergic conjunctivitis is considered to be a type I
hypersensitivity reaction. Its treatment is largely supportive, although in severe cases, topi‐
cal corticosteroids may be of some benefit 1.
Figure 4. Irritant conjunctivitis- generalised redness around the eye and constant tearing are typical features
Irritant  conjunctivitis  is  a  form of  conjunctivitis  that  is  often  bought  on  by  an  external
source. The source, considered an ‘irritant’, directly affects the conjunctiva, causing an in‐
flammatory response. Not all causes of irritant conjunctivitis are external however. Caus‐
es  of  irritant  conjunctivitis  are  vast,  though some of  the  more  common causes  are  hair
products (e.g. shampoos), smoke or fumes, chlorinated water used in swimming pools. A
common non-external source is trapped eyelashes, which continually irritate the conjunc‐
tiva.  Treatment  of  irritant  conjunctivitis  is  thorough cleansing of  the  eye  and removing
the irritant.
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2. Infectious conjunctivitis
Infective conjunctivitis can be caused by several bacterial and viral pathogens. Infective con‐
junctivitis can be further differentiated into acute infective conjunctivitis, defined as inflam‐
mation of the conjunctiva due to infection that does not last longer than 3 weeks, and
chronic conjunctivitis, inflammation of the conjunctiva that lasts longer than 3 weeks.
In the developed world, acute infectious conjunctivitis is a common presentation in the pri‐
mary care setting, accounting for up to 2% of consultations with the general practitioner [ 2].
Many general practitioners find it difficult to differentiate between bacterial and viral con‐
junctivitis. The uncertainty of the pathogenic cause of acute conjunctivitis has led to the rou‐
tine practice of prescribing a broad spectrum antibiotic topically even though the pathogen
has not been proved to be bacterial in nature. In the UK, approximately 3.4 million topical
antibiotic prescriptions are issued every year, at a cost to the NHS of over £4.7 million [3].
A diagnosis of conjunctivitis is usually made on the basis of a clinical history and examina‐
tion by the clinician. Other investigations of conjunctivitis, such as swabs and cultures of the
conjunctiva are rarely performed as it often delays treatment and has very little prognostic
benefit, as conjunctivitis is often a self limiting illness and the antibiotics currently used have
a good spectrum of pathogen coverage. Swabs and cultures are mainly used in research pur‐
poses.
It is vital that a correct diagnosis is made to early to identify the cause and start treatment
promptly. It is also essential to rule out more serious causes and medical emergencies that
would require hospital admission. Such cases would include bacterial keratitis, acute closed
angle glaucoma, corneal abrasions and others.
2.1. Bacterial conjunctivitis
Bacterial conjunctivitis is a relatively common infection and affects all people, although a
higher incidence is seen in infants, school children and the elderly. Bacterial conjunctivitis
has a higher prevalence in children, where a recent study by Rose et al identified 67% of 326
children as having a bacterial cause [4]. Although its incidence is continuing to decrease in
developing nations, periodic rises in incidence are seen during the monsoon seasons in
many countries such as Bangladesh, and thus, bacterial conjunctivitis is the most common
cause of infective conjunctivitis in developing nations.
2.1.1. Types of bacterial conjunctivitis and pathogenic causes of bacterial conjunctivitis
Bacterial conjunctivitis can be broadly split into three major categories; hyperacute bacterial
conjunctivitis, acute conjuncitivis and chronic conjunctivitis.
• Hyperacute bacterial conjunctivitis is commonly seen in patients affected with N. Gonor‐
rhoea. The onset is often rapid with an exaggerated form of conjunctival injection, chemosis
and copious purulent discharge. Prompt treatment is essential to prevent complications.
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• Acute bacterial conjunctivitis is the most commonly seen bacterial conjunctivitis and often
presents with a typical presentation, time course and prognosis. In a study done by Weiss
et al, the most common pathogens in acute bacterial conjunctivitis were Staphylococcus
aureus, Haemophilus influenzae, streptococcus pneumoniae, and Moraxella catarrhalis, whereas
in an older study done by Gigilotti et al, Chlamydia trachomatis was also commonly found
in infected patients [5, 6].
• Chronic bacterial conjunctivitis, ie, red eye with purulent discharge persisting for longer
than a few weeks, is generally caused by Chlamydia trachomatis or is associated with a
nidus for infection such as in dacryocystitis [7].
In certain bacterial conjunctivitis, it is essential to identify a pathogen. As mentioned, most
causes of conjunctivitis are diagnosed and treated on a clinical exam basis, but in patients
who are particularly susceptible such as neonates or immunodeficient patients, a microbio‐
logical diagnosis must be made to exclude harmful pathogens such as N.gonorrheae, Listeria
monocytogenes, Corynobacterium diptheriae and certain members of the Haemophilus group.
These pathogens contain proteolytic enzymes which may cause long term damage to the pa‐
renchyma of the conjunctiva.
2.1.2. Signs and symptoms of bacterial conjunctivitis
Although the symptoms of bacterial conjunctivitis are varied and quite vast, there are a
number of key symptoms which differentiate it from other eye infections. Thick purulent
discharge is seen as the major symptom that affects sufferers of bacterial conjunctivitis, com‐
pared to the watery discharge seen in viral conjunctivitis. This leads to ‘glue eye’ which is
often the term used to describe difficulty opening the eye due to thick sticky secretions. A
study done in 2004 in the Netherlands confirmed that ‘early morning glue eye’ was a posi‐
tive predictor of bacterial conjunctivitis amongst 184 patients presenting with ‘glue eye’, itch
or a past history of conjunctivitis [8].
Figure 5. Mucopurulent discharge seen in bacterial conjunctivitis
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Figure 6. Injection of the conjunctiva and chemosis are two common symptoms and are demonstrated here
Other symptoms which are commonly seen in bacterial conjunctivitis is a ‘foreign body’ sen‐
sation, injection of the conjunctiva, chemosis (conjunctival oedema), itching, erythema of the
eyelid skin and some patients also experience a slight burning or stinging sensation. In stud‐
ies done by Carr et al and Wall et al almost all patients presented with injection of the con‐
junctiva, up to 90% of patients with bacterial conjunctivitis presented with itching and a
foreign body sensation and up to 50% of patients presented with a burning or stinging sen‐
sation [9, 10]. Erythema of the eyelid was seen in 85% of patients.
2.1.3. Complications of bacterial conjunctivitis
Bacterial keratitis is a well known but rare complication of bacterial conjunctivitis [11]. Peo‐
ple at particularly high risk of developing keratitis often have corneal epithelial defects or
disease and patients who have particularly dry eyes are seen to be at an increased risk.
2.1.4. Treatment of bacterial conjunctivitis
Bacterial conjunctivitis is commonly treated empirically with broad-spectrum antibiotics.
Broad-spectrum antibiotics that have good efficacy against both gram-negative and gram-
positive are necessary as a diverse range of pathogens can be the cause of infections. A Co‐
chrane systematic review found that acute bacterial conjunctivitis is often a self-limiting
condition, 65% (95% confidence interval of 59% to 70%) patients treated with placebo
showed significant improvement occurring by the second to fifth day of infection [12]. Pa‐
tients treated with topical antibiotics were shown to have improved clinical outcome, espe‐
cially when treated early (days 2 to 5) with relative risk = 1.24, 95% confidence interval = 1.05
to 1.45. Patients treated late (days 7 to 10) had reduced clinical benefit with relative risk =
1.11, 95% confidence interval = 1.02 to 1.21. Microbiological remission was also improved
with treatment, early (days 2 to 5) showing relative risk = 1.77, 95% confidence interval =
1.23 to 2.54 and late (days 7 to 10) relative risk = 1.56, 95% confidence interval= 1.17 to 2.09.
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An open, randomized and controlled study by Everitt et al investigated 307 adults and chil‐
dren with suspected infective conjunctivitis using three different treatment methods: no
treatment, delayed topical treatment and immediate topical chloramphenicol treatment [13].
The varying treatments did not affect the severity of symptoms experienced within the first
three days of infection. However, patients with moderate symptoms who were treated im‐
mediately with topical chloramphenicol had a reduced duration of symptoms with an aver‐
age of 3.3 days whilst patients that received no treatment had 4.9 days duration.
Rietveld et al carried out a double-blind randomized and placebo controlled study in a pri‐
mary care setting. The efficacy of fusidic acid gel was compared to a placebo gel in 163 adult
patients presenting with a red eye and mucopurulent discharge [14]. After 7 days the treat‐
ments were evaluated with clinical cure being found in 62% of patients on fusidic acid gel
and 59% of patients on placebo gel. The study found that the severity of symptoms and the
duration of symptoms were not significantly different in either group. In conclusion, with
the limited evidence the authors produced, they did not support the current practice of pre‐
scribing empirical antibiotics.
The majority of doctors actively treat uncomplicated acute bacterial conjunctivitis with em‐
pirical topical antibiotics at diagnosis. There are several other options available including:
delaying treatment for 5 days and begin treatment if no sign of improvement and to treat
patients who have clinical features associated with a bacterial cause. Studies comparing the
effectiveness of different antibiotics recommended for use in suspected bacterial conjunctivi‐
tis have shown similar levels of effectiveness. Therefore, it is important to consider local bac‐
terial resistance and cost-effectiveness of the antibiotics being prescribed [15]. All antibiotic
courses should be taken for 7-10 days. Compliance with the length of time the antibioticsare
prescribed for is particularly important to help prevent resistance developing.
The first line treatment in mild to moderate bacterial conjunctivitis is either Trimethoprim-Pol‐
ymyxin B (Polytrim) solution, Erythromycin 0.5% ointment, or Azithromycin drops. Alterna‐
tives to these antibiotics are bacitracin ointment and sulfacetamide drops. In moderate to
severe infections, or antibiotic-resistant infections and in immunocompromised patients, fluo‐
roquinolones are recommended. These include: ofloxacin, ciprofloxacin, levofloxacin, moxi‐
floxacin  and  gatifloxacin.  Chlamydial  conjunctivitis  requires  oral  antibiotics  alongside  a
topical antibiotic to treat the systemic infection alongside the ophthalmic manifestation. The
oral antibiotic options include Azithromycin, doxycycline, or erythromycin. These are given in
combination with Azithromycin or erythromycin drops for 2 to 3 weeks [16]. In addition, pa‐
tients should be advised to take several precautions to help prevent spread of infection. Pa‐
tients  should  wash  their  hands  regularly  and thoroughly,  especially  after  touching  any
infected secretions. Furthermore, patients should avoid sharing towels, pillows, or utensils.
Studies have shown that treatment with topical antibiotics shortens the duration of disease,
prevents spread of infection, reduces the rate of recurrence, and decreases the risk of com‐
plications that effect vision [17].However, there has been controversy in recent years over
the use of empirical antibiotics and its role in an evidently self-limiting disease with the clin‐
ical outcome being only marginally favourable to taking no antibiotics. There has been in‐
creasing antibiotic resistance especially among the older class of antibiotics that have been
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used extensively such as chloramphenicol, sulphonamides, polymyxins, bacitracin, amino‐
glycosides and early generation fluoroquinolones. The efficacy of these drugs has reduced
to a combination of resistance and narrow spectrum of activity [18, 19].The newer genera‐
tion of fluoroquinolones, such as gatifloxacin and moxifloxacin, have a greater range of ac‐
tivity and efficacy against common pathogens of the eye [20].Specifically, they have better in
vitro efficacy over the older generation fluoroquinolones against gram positive pathogens.
However, the efficacy was not greater with Haemophilus influenza isolates [21]. The Ocular
Tracking Resistance in the U.S. Today (TRUST) initiative annually monitors the in vitro sus‐
ceptibility of common ocular pathogens; Staphylococcus aureus, Streptococcus pneumonia,
and Haemophilus influenzae. Between 2000 and 2005 there was a 12.1% increase in the inci‐
dence of methicillin-resistant Staphylococcus aureus (MRSA). Moreover, greater than 80% of
the MRSA strains were also resistant to fluoroquinolones [22, 23].
2.1.5. Prognosis of bacterial conjunctivitis
The prognosis of bacterial conjunctivitis is normally very good with the correct and prompt
treatment of the infection. In many cases, spontaneous remission, without a cure, is seen. In
a study done by Sheikh and Hurwitz et al, spontaneous cure occurred in 60% of patients
within 1-2 weeks [24]. However, with prompt antibiotic treatment, the treatment time is sig‐
nificantly reduced.
2.2. Viral conjunctivitis
Viral conjunctivitis is a common infection amongst the Western population, and is often as‐
sociated with other infections around the body. Due to the contiguity with the respiratory
tract anatomy, viral upper respiratory tract infections are a common cause of secondary vi‐
ral conjunctivitis.
Most cases of viral conjunctivitis are mild. Days 3-5 of infection are often the worst, but the
infection will usually clear up in 7–14 days without treatment and without any long-term
consequences. In some cases, viral conjunctivitis can take 2-3 weeks or more to clear up, es‐
pecially if complications arise.
2.2.1. Pathogens causing viral conjunctivitis
Much unlike bacterial conjunctivitis, there are many pathogens associated with viral con‐
junctivitis, although the majority of cases of viral conjunctivitis are encompassed by a few
common pathogens. The specific viruses are much dependant on the geographical area in
the world. In a study done in the Far East countries of Japan, Korea and Taiwan the most
common pathogens isolated from 1105 cases were adenovirus 8 and enterovirus 70. Other vi‐
ruses also identified were adenoviruses 19 and 37 [25]. Similarly, the causes of viral conjuncti‐
vitis in the Western countries are mainly adenoviruses, though adenovirus 13 seems to be the
dominant strain in these countries.
Other rarer causes of viral conjunctivitis include herpes simplex virus, herpes zoster virus and
the measles virus. Although less commonly seen, it is essential to identify herpes and measles
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viruses early to ensure prompt treatment, to prevent any long term complications associated
with these viruses.
A recent study also showed outbreaks of the avian influenza viruses in patients, although this
may possibly be linked to the recent outbreaks of the virus in humans.
2.2.2. Signs and symptoms of viral conjunctivitis
As with bacterial conjunctivitis, a diagnosis of viral conjunctivitis is often made by the gen‐
eral practitioner on the basis of a history and examination. However, due to the overlap in
symptoms between viral and bacterial conjunctivitis, it is often difficult to ascertain viral
from bacterial conjunctivitis.
Figure 7. Classical ‘pink’ eye associated with conjunctival injection seen in viral conjunctivitis
Figure 8. Classical follicles seen in the conjunctiva in a patient suffering from herpetic conjunctivitis
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The key symptom of viral conjunctivitis is ‘pink eye’. This shows a fine, diffuse pinkness of
the conjunctiva, which is often easily mistaken for the ciliary injection of iritis. Other symp‐
toms associated with viral conjunctivitis include discharge which is often clear and watery.
This is often the most discernible difference between bacterial and viral conjunctivitis.
A history of itchy eyes is also suggestive of viral conjunctivitis, although it is a symptom al‐
so associated with irritant and allergic conjunctivitis. Rarer symptoms associated with sim‐
ple adenovirus viral conjunctivitis include foreign body sensation, ocular discomfort,
excessive tearing and sticky eyelids which are worse in the morning.
Herpes simplex conjunctivitis is usually unilateral. Symptoms include a red eye, photophobia,
eye pain and mucoid discharge. There may be periorbital vesicles, and a conjunctival
branching (dendritic) pattern of fluorescein staining makes the diagnosis.
Below is a table summarising the key differences between adenoviral and herpetic viral con‐
junctivitis.
Adenoviral Herpetic
Watery discharge bilaterally Usually unilateral watery discharge
Hyperaemia Diffuse hyperaemia
Petechial hemorrhages Vesicular eruptions on eyelid
Punctate keratitis Follicles
Preauricular and/or submandibular lymphadenopathy Occasional preauricularlypmphadenopathy
Serous, mucoid, or mucopurulent discharge Serous mucoid discharge
Associated with pharyngitis Major complication of dendritic epethilial keratitis
Table 1. A summary of the differences of adenoviral and herpetic viral conjunctivitis
Herpes zoster Ophthalmicus is shingles of the opthalmic branch of the trigeminal nerve,
which innervates the cornea and the tip of the nose. It begins with unilateral neuralgia, fol‐
lowed by a vesicular rash in the distribution of nerve. Once spread to the eye, it may lead to
an extremely painful conjunctivitis and may take several days to settle.
2.2.3. Complications of viral conjunctivitis
There are many recognised complications of viral conjunctivitis. In many cases, it may be
associated with inflammation of the cornea, known as keratoconjunctivitis. There is also an
increase in likelihood of a superimposed bacterial infection. Other rare complications associ‐
ated with viral conjunctivitis include blepharitis, entropion and in very rare cases, scarring
of the eyelid.
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Figure 9. Herpes simplex keratitis, demonstrated here via fluorescein staining
The most serious complication of viral conjunctivitis is herpes simplex keratitis, a corneal ul‐
cer, which can ultimately lead to blindness. This is an extremely rare side effect of viral con‐
junctivitis and requires immediate transfer to hospital and review by the ophthalmologists.
2.2.4. Treatment of viral conjunctivitis
Viral conjunctivitis is a self-limiting disease that usually resolves within two weeks of onset of
symptoms and does not require treatment with antiviral medication. There is no evidence sup‐
porting the use of anti-viral medication and their efficacy has not been proven. However, as a
highly contagious disease, there is a need to make infected patients aware of good hygiene
practices to prevent further spread. Viral conjunctivitis is transmitted through direct contact,
therefore, hands should be thoroughly washed regularly, and infected patients should not
share pillows, towels and other utensils [26].The highly contagious nature of viral conjunctivi‐
tis, especially adenovirus, makes it necessary for infected patients to avoid going to work or
school for 5 days to 2 weeks. Contagiousness of adenovirus conjunctivitis has been shown to be
reduced in an in vitro study using the topical anti-viral agent povidone-iodine. Povidone-io‐
dine at a concentration of 1:10 (0.8%) is particularly effective against free adenovirus, eradicat‐
ing all of them within 10 minutes with little cytotoxicity [27]. In addition, patients with contact
lenses should avoid using them until the conjunctivitis resolves and last dose of any treatment
having been taken over 24 hours ago [28]. Treatment for viral conjunctivitis is supportive, in‐
volving cold compresses, ocular decongestants, and artificial tears for symptomatic relief. In
patients with high susceptibility of contracting bacterial infections an antibiotic may be given
to prevent a bacterial superinfection occurring.If a pseudomembrane or corneal subepithelial
infiltrates develop then a topical corticosteroid may be given alongside the other non-pharma‐
cological treatments outlined earlier. Immediate referral to an ophthalmologist should be con‐
sidered in patients with a psuedomembrane or corneal subepithelial infiltrate. Immediate
referral is necessary in patients with hyperacute conjunctivitis or those who have corneal in‐
volvement including ulceration and herpetic keratitis.
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2.2.5. Prognosis of viral conjunctivitis
Viral conjunctivitis is extremely contagious and remains so for 14 days, which also is often
how long the symptoms remain.
The prognosis is very good for viral conjunctivitis. It resolves completely within 2 weeks of
the ‘pink eye’ onset and there are rarely any long term complications or problems associated
with viral conjunctivitis [29].
3. Conjunctivitis in the immunocompromised
Conjunctivitis in the immunocompromised is something that is often overlooked by the gen‐
eral practioner. However, it is essential to properly investigate conjunctivitis in immunodefi‐
cient patients as they are more likely to suffer from long term complications such as
dendritic ulcers and corneal damage.
3.1. Epidemiology and conjunctival microvascular disease associated with HIV
Up to 75% of HIV infected patients have suffered from conjunctivitis. Most will exhibit mi‐
crovascular changes of the conjunctiva, often the inferior perilimbal bulbar conjunctiva.
These changes are often seen as capillary dilations, short irregular vessels and a granular ap‐
pearance of blood column within the vessels.
In some cases, there have been reports of direct infiltration of the vascular endothelial cells
of the conjunctiva being infiltrated by the HIV virus, which causes a deposition of immune
complexes within the conjunctiva, causing conjunctivitis.
3.2. Infections causing conjunctivitis in the immunocompromised
Most conjunctivitis reports in the immunocompromised, especially HIV, have shown staphy‐
lococci to be the main infective agent, with coagulase negative staphylococci (mostly staphylococ‐
cal epidermidis the majority) accounting for most of the cases. The major other normal flora
organism which cause infection in immunocompromised patients include cornybacterium
pseudo/diphtherticum(found in the nasopharynx) and certain members of the Haemophilus
group. Isolated cases of neisseriameningitidisand the measles virus have also been found in im‐
munocompromised patients, although no study has yet shown a direct link between these
two organisms and conjunctivitis in the immunocompromised.
Opportunistic infections may also cause conjunctivitis. Below are common pathogens that
have been identified as opportunistic infections causing conjunctivitis:
• Microsporidial keratoconjunctivitis- Reports of microsporidial keratoconjunctivitis in
AIDS patients have been noted. This infection is caused by an intracellular protozoan par‐
asite of the phylum Microspora. Patients affected with Microsporidial keratoconjunctivitis
experience similar symptoms as with any other bacterial infection, but the symptoms of
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photophobia and extreme redness are also present. There may also be bilateral conjuncti‐
val hyperaemia with diffuse coarse white infiltrates, conjunctival hypertrophy and ero‐
sions of the corneal epithelium [30].
Microsporidial keratoconjunctivitis should not be overlooked in HIV patients because it
rarely responds to conventional topical antivirals or antibacterials. In some cases, antiproto‐
zoal medication has also been reported as ineffective. A recent study found that Fumagillin
(Fumidin B) is the treatment with most positive outcome in HIV patients with Microspori‐
dial keratoconjunctivitis [31].
Figure 10. Conjunctivitis in a patient suffering from AIDS
• Molluscum contagiosum-Although rarely affecting the conjunctiva even in immunocom‐
promised individuals, molluscum contagiosum has been noted to primarily affect the
conjunctiva and also cause secondary conjunctival inflammation during infection. In one
case report, a nodule of molluscum contagiosum was noted on the bulbar conjunctiva on
a 34 year old man with AIDS [32]. However, in most cases of patients in an immunocom‐
promised state with molluscum contagiosum, the conjunctiva is secondarily affected,
causing an associated follicular conjunctivitis [33].
Treatment of primarily conjuctival infection of molluscum contagiosum is via cryotherapy
and/or surgery, although this has shown to provide only limited long term correction in
HIV patients.
• Fungal infections- Fungal infections affecting the conjunctiva are rare. In immunocompro‐
mised patients, the cornea is often affected, causing a keratitis to develop. This can how‐
ever, cause a secondary conjunctivitis. Studies have shown that Cryptococcus and Candida
albicans are the most common pathogens affecting the cornea and conjunctiva in immuno‐
compromised patients.
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Fortunately, the treatment is very effective for fungal infections. Although hospital admis‐
sion is required in patients affected with keratitis, topical amphotericin B or natamycin, sub‐
conjunctival miconazole and oral ketoconazole are proven effective antifungals.
4. Neonatal conjunctivitis
Neonatal conjunctivitis also known as ophthalmia neonatorum is inflammation of the con‐
junctiva occurring in the first month of life. This condition is caused by a number of differ‐
ent pathogens. These include bacteria, viruses and chemical agents. In recent times
prophylaxis has led to decreased morbidity in the developed world. However, it is still a
significant cause of ocular morbidity, blindness and even death in the developing world.
4.1. Epidemiology of neonatal conjunctivitis
The incidence of ophthalmia neonatorum is dependent on many different factors. The main
risk factor for ophthalmia neonatorum of infective origin is the presence of a sexually trans‐
mitted disease in the mother. The organism usually infects the neonate through direct con‐
tact as it  passes through the birth canal.  Therefore,  incidence is high in areas with high
rates of sexually transmitted disease [34]. Prolonged rupture of membranes at the time of
delivery is also thought to increase the risk of infection. It is also dependent on socioeco‐
nomic factors; incidence varies in highly developed countries with good prenatal care com‐
pared  to  the  developing  parts  of  the  world  [35].  The  offending  pathogens  vary
geographically due to the differences in the prevalence of maternal infection and the use of
prophylaxis. In US and Europe the incidence has been reported 1-2% depending on the so‐
cioeconomic character of the area. However in other parts of the world the incidence is re‐
ported to be as high as 17%. In recent studies in Pakistanthe incidence has been 17% and in
Kenya as high 23% [36, 37].
There has been a sharp decrease in the incidence of ophthalmia neonatorum in the past few
decades in the developed countries due to many reasons. In 1800s, prophylaxis (silver ni‐
trate) for ophthalmia neonatorum in the developed countries was used for the first time.
Since then there has been gradual decrease in incidence. Better prenatal care has also led to
detection and treatment of sexually transmitted diseases hence reduction in the risk of trans‐
mission to new-borns during birth.
4.2. Aetiology of neonatal conjunctivitis
Ophthalmia neonatorum can be broadly divided into two types, septic and aseptic. The
aseptic type (chemical conjunctivitis) is generally secondary to the instillation of silver ni‐
trate drops for ocular prophylaxis. Septic neonatal conjunctivitis is mainly caused by bacteri‐
al and viral infections. Causes include [38]:
From maternal genital tract:
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• Bacterial
◦ Neisseria gonorrhoeae
◦ Chlamydia trachomatis
◦ Group B beta-haemolytic streptococci
• Viral
◦ Herpes Simplex Virus (HSV)
From cross infection:
• Staphylococcus aureus
• Coliforms
• Pseudomonas aeruginosa
Figure 11. A neonate suffering from gonococcal conjunctivitis
Neisseria gonorrhoeae - Congenital gonorrhoea infection is acquired intrapartum and it leads
to ophthalmia neonatorum. Gonococcal ophthalmia neonatorum presents with a severe con‐
junctivitis and keratitis usually in the first 48 hours of life but it can be delayed up to 3
weeks. It is frequently bilateral. If untreated, it can lead to blindness. Systemic infection can
cause meningitis, arthritis and sepsis.
Chlamydia trachomatis - Also known as trachoma-inclusion conjunctivitis or TRIC.This is usu‐
ally a benign, self-limiting, suppurative conjunctivitis due to Chlamydia trachomatis - sero‐
types D-K. Onset occurs around 1 week of age. Onset maybe earlier with premature rupture
of membranes. It is characterised by mild swelling, hyperaemia and minimal to moderate
discharge.
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Figure 12. Typical presentation of a neonate suffering from herpetic conjunctivitis
Other bacteria -These bacteria make up 30-50% of all cases of neonatal conjunctivitis. The
most commonly identified gram-positive organisms include Staphylococcus aureus, Strepto‐
coccus pneumoniae, Streptococcus viridans, and Staphylococcus epidermidis. Gram-negative or‐
ganisms, such as Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Proteus,
Enterobacter, and Pseudomonas species, also have been implicated.
Herpes Simplex- Herpes simplex virus (HSV) can cause neonatal keratoconjunctivitis. This is
a rarer form of ophthalmia neonatorum presenting in the second week of life and can be as‐
sociated with a generalized herpes simplex infection.
Chemical Conjunctivitis- Classically, the most common cause of neonatal conjunctivitis is due
to use of post-delivery use of ophthalmic silver nitrate used in the prophylaxis of ocular
Gonococcal infections. There is a mild irritation, tearing and redness in a baby who has been
administered prophylactic silver nitrate (used for the prevention of gonorrhoeal infection)
within the preceding 24-48 hours. The incidence of chemical conjunctivitis in the United
States has significantly decreased since replacement of silver nitrate with erythromycin oint‐
ment.
4.3. Presentation of neonatal conjunctivitis
Babies present with unilateral or bilateral purulent, mucopurulent or mucoid discharge
from the eyes within the first month of life. Injected conjunctiva and lid swelling may also
be present. There may be associated systemic infection.
• Bacterial conjunctivitis - often have a longer incubation period than for the other infective
causes. Presenting with a sub-acute onset between the 4th and 28th day of life. Depending
on the pathogen, there may be a mixed picture of a red eye with lid swelling and a vary‐
ing amount of purulent discharge. Specific types of bacterial infection:
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• Chlamydial infection - 5 to 14 days after birth (some report up to 28 days after birth): uni‐
lateral/bilateral watery discharge which becomes copious and purulent later on. There
may be associated preseptal cellulitis and, less commonly, rhinitis, otitis and pneumonitis.
• Gonorrhoeal infection - typically 1-5 days after birth but may occur later: hyper-acute con‐
junctival injection and chemosis, lid oedema and severe purulent discharge. There may be
associated corneal ulceration and perforation.
• Viral conjunctivitis
• The onset is acute usually 1-14 days after birth: unilateral/bilateral serosanguinous dis‐
charge ± vesicular skin lesions. Uncommonly it can also lead to systemic infection.
4.4. Differential diagnosis of neonatal conjunctivitis
Every other potential cause of red eye needs to be excluded. The differentials include [39]:
• Dacryocystitis
• Congenital glaucoma
• Nasolacrimal duct obstruction
• Preseptal/Orbital cellulitis
• Congenital glaucoma
• Infectious keratitis
4.5. Investigations
A definitive diagnosis of the cause of ophthalmia neonatorum is dependent on laboratory
identification of the offending organism. The speed of progression of some of the causative
agents makes it imperative to do a test which can identify the cause as soon as possible.
Some of the laboratory tests that can be performed are as follows [40]:
• Culture on chocolate agar for N gonorrhoeae. Due to the rapid progression of N gonorrhoea
conjunctivitis, it makes it imperative to perform smears, as it may be possible to identify
gram-negative diplococci and initiate proper treatment within hours.
• Conjunctival scraping with Gram stain and Giemsa stain for chlamydia. Conjunctival
specimens for chlamydia testing must include conjunctival epithelial cells because C. tra‐
chomatis is an obligate intracellular organism and exudates are not adequate for testing.
Other non-culture methods such as direct fluorescent antibody testing, enzyme immuno‐
assays and nucleic acid testing (NAT) may allow early detection of Chlamydia within
hours rather than several days, as required for culture methods.
• Culture on blood agar for other strains of bacteria. For other viral aetiology direct cultures
of the HSV vesicles can be performed. Alternatively direct antibody testing or PCR can be
done. If symptoms worsen or symptoms recur after treatment cultures may have to be re‐
peated.
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4.6. Management of neonatal conjunctivitis
Prophylaxis- In 1881 for the first time silver nitrate was used as prophylactic treatment to
reduce the incidence of ophthalmia neonatorum. Silver nitrate is specifically more effective
against gonorrhoeal conjunctivitis. It inactivates gonococci by agglutination. It is not effec‐
tive against Chlamydial conjunctivitis. However silver nitrate use also led to mild conjuncti‐
val inflammation, tearing and redness which typically resolved within 48 hours. Chemical
conjunctivitis is a self-limiting condition, therefore no treatment is required. However pres‐
ervative artificial tears have been used in some cases.
In recent times povidone-iodine drops are used as prophylaxis instead of silver nitrate [41].
These are shown to be more effective against gonococcal and chlamydial conjunctivitis and al‐
so less toxic. In US, erythromycin is being used as alternative to silver nitrate and povidone-
iodine [42]. This is also well tolerated and effective against TRIC and gonococci agents.
Treatment -Treatment of neonatal conjunctivitis should initially be based on the history,
clinical presentation and results of smears. This can later be adjusted when laboratory re‐
sults become available then specific therapy can be instituted.
The risk of transmission of chlamydial, gonococcal, herpetic, and streptococcal pathogens to
the foetus during the birth process should be considered. If necessary, cervical cultures
should be performed and managed appropriately. To confirm the presence of a sexually
transmitted disease in the neonate, examine and treat the mother and her sexual partner. If
necessary, therapy can be modified when the results of culture and sensitivity are known.
Bacterial conjunctivitis- Chlamydial conjunctivitis is treated with fourteen day course of
twice daily oral erythromycin(50 mg/kg/d divided qid) [43, 44]. Systemic therapy is impor‐
tant in Chlamydia conjunctivitis, due to the high incidence of extra-ocular infection in neo‐
nates. It has shown to eliminate Chlamydial infection in 80-100% of patients. Topical
erythromycin can be used as adjunct with the oral therapy. If there is failure to respond to
this course the fourteen day course can be repeated before seeking alternative antibiotics
[45].
Gonococcal conjunctivitis may be treated with intramascular or intravenous ceftriaxone 50
mg/kg/day or as a single dose treatment of 125mg [46]. Alternatively, cefotaxime 100mg can
be given intramuscularly or 25 mg/kg given either intramuscularly or intravenously every
12 hours for 7 days [47].
Neonates with conjunctivitis caused by herpetic simplex virus should be treated with sys‐
temic acyclovir to reduce the chance of a systemic infection [48]. An effective dose is 60
mg/kg/day IV divided.The recommended minimal duration is 14 days, but a course as long
as 21 days may be required.Infants with neonatal HSV keratitis should receive a topical oph‐
thalmic drug, most commonly 1% trifluridine drops or 3% vidarabine ointment.
4.7. Complications of neonatal conjunctivitis
Complications of neonatal conjunctivitis vary. There are two main types of complications,
ocular and systemic complications. These can be prevented with prompt diagnosis and
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treatment. Ocular complications include pseudomembrane formation, peripheral pannus
formation, thickened palpebral conjunctiva, cornealoedema, corneal opacification, corneal
perforation, staphyloma, endophthalmitis, loss of eye, and blindness [49].
Systemic complications of chlamydia conjunctivitis include pneumonitis, otitis, and phar‐
yngeal and rectal colonization. Pneumonia has been reported in 10-20% of infants with chla‐
mydial conjunctivitis. Complications of gonococcal conjunctivitis and subsequent systemic
involvement include arthritis, meningitis, anorectal infection, septicaemia, and death.
Ophthalmia neonatorum is a preventable cause of childhood blindness and with prompt di‐
agnosis, treatment and efforts on all levels, this can be eradicated.
5. Prevention of conjunctivitis
Infective conjunctivitis is a condition which affects people of all ages. Its spread is something
that can be effectively controlled via good personal hygiene and adequate education. Once
an individual is affected, rapid measures must be taken to ensure that the spread is limited.
Good personal hygiene is primarily achieved via effective hand washing and eye care.
Where an outbreak of the highly contagious viral conjunctivitis has occurred, stringent
measures to control the spread must be undertaken immediately. Simple measures such as
removal of possible contaminated materials (hand cloth, towels and face cloths) are very ef‐
fective in reducing spread.
For specialist cases of conjunctivitis, i.e. neonatal conjunctivitis and conjunctivitis in the im‐
munocompromised, immediate action must be undertaken to ensure no long term complica‐
tions and quick recovery. Should there be any delay in treatment, the potential for long term
damage, and even blindness, is very high. Prevention of such conditions can be attained by
immediate and frequent treatment via hospital admissions, prophylactic medication and
good eye hygiene.
6. Conclusion
Conjunctivitis can be a very irritating and frustrating condition to suffer from. Not only
does it have profound social implications, it can also affect education and finances if social
exclusion is required. General practitioners must remain vigilant when diagnosing viral
from bacterial conjunctivitis and try to ensure that patient education of the condition is at an
optimum level to prevent spread. Special care must also be taken into consideration in neo‐
natal conjunctivitis and conjunctivitis in the immunocompromised.
Although conjunctivitis is mostly a mild condition, GPs must also be aware of other more
serious conditions and be able to differentiate mild conditions from more serious underlying
and emergency conditions. This is only achieved via being able to create a list of differentials
from a thorough patient history, examination and referral to an ophthalmologist if required.
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